News

World Precision Instruments (WPI), the global leader in transepithelial electrical resistance (TEER) technology, in collaboration with SynVivo, a leader in organ-on-chip (OOC) solutions, is proud to announce the launch of the EVOMTM Chip – a revolutionary multiplex TEER system designed specifically for real-time, non-destructive monitoring of OOC platforms.

Co-developed to support SynVivo’s state-of-the-art Blood-Brain Barrier (BBB) OOC model, the EVOM™ Chip enables on-chip, multiplex TEER measurements with embedded electrodes. This innovation allows researchers and drug developers to continuously monitor up to 12 OOCs for barrier integrity while simultaneously enabling fluidics and imaging, offering hands-free operation with enhanced accuracy, precision, and reproducibility.

SARASOTA, Fla. and PARIS, France, October 14, 2024 -- World Precision Instruments (WPI), a leading provider of high-quality laboratory instruments and equipment for basic research and drug development, and ELVESYS, a leading microfluidic instrument manufacturer specializing in flow control and microfabrication, are excited to announce a global commercial partnership for the distribution of the ELVEFLOW family of products. This distribution partnership aims to broaden WPI's offering in fluidics, continuing to position WPI at the forefront of developing technologies that enable and augment microphysiological systems and organs-on-chip applications. With a strong focus on enabling TEER, fluidics, and other vital technologies in this field, WPI is committed to advancing research and innovation in the life sciences for basic research and drug development.

A new study by Altis Biosystems (Durham, NC) using the EVOM™ Auto is undergoing a peer review prior to publication. It addresses the challenge of predicting gastrointestinal toxicities (GITs) in drug development, which are common adverse events in clinical trials. ​ Traditional animal models fail to accurately replicate human GI physiology, leading to late detection of GITs. ​ Researchers Colleen Pike and James Levi (with their team) developed a high-throughput assay, a 2D human intestinal stem cell-derived model, which assesses cell proliferation, cell abundance, and barrier function to predict clinical diarrhea risk.

See how WPI equipment is being used by researchers to advance organ on a chip (OOC) to improve the outcomes of pregnancies. WPI is working with Dr. Ramkumar Menon, director of UTMB Obstetrics and Gynecology’s Division of Basic Science and Translational Research, who is using Transepithelial Electrical Resistance (TEER) to explore ways to minimize pre-term births.

A new study by Altis Biosystems (Durham, NC) using the EVOM™ Auto is undergoing a peer review prior to publication. It addresses the challenge of predicting gastrointestinal toxicities (GITs) in drug development, which are common adverse events in clinical trials. ​ Traditional animal models fail to accurately replicate human GI physiology, leading to late detection of GITs. ​ Researchers Colleen Pike and James Levi (with their team) developed a high-throughput assay, a 2D human intestinal stem cell-derived model, which assesses cell proliferation, cell abundance, and barrier function to predict clinical diarrhea risk.

SARASOTA, Fla. and LYON, France, June 10, 2024 /PRNewswire/ -- World Precision Instruments (WPI), a leading provider of high-quality laboratory instruments and equipment for basic research and drug development, and NETRI, an organs-on-chip industrial start-up, are proud today to announce their partnership. This partnership aims to associate WPI's transepithelial electrical resistance (TEER) technology, and products enabling TEER, with NETRI's proprietary NeoBento organs-on-chip MultiFluidics™ line. WPI has long been at the forefront of developing technologies that enable and augment microphysiological systems and organs-on-chip applications. With a strong focus on enabling TEER, fluidics, and other vital technologies in this field, WPI is committed to advancing research and innovation in the life sciences for basic research and drug development.

SARASOTA, Fla., November 10, 2023 /PRNewswire/ -- World Precision Instruments (WPI), a leading provider of high-quality laboratory instruments and equipment for basic research and drug development, is proud to announce the establishment of its Scientific Advisory Board (SAB). Comprised of renowned experts in various scientific disciplines, the SAB will play a crucial role in guiding and advancing WPI's commitment to innovation and excellence in scientific research.

SARASOTA, Fla., October 23, 2023 /PRNewswire/ -- World Precision Instruments (WPI) is excited to expand the capability of the EVOM™ Auto, now offering both 24 and 96 multiwell capacity in one single platform.  The EVOM™ Auto enables rapid and reproducible measurements of Transepithelial Electrical Resistance (TEER), a well-established, non-invasive and widely accepted method of evaluating epithelial and endothelial cells and tissues. 

On December 29, 2022, the FDA Modernization Act 2.0 was signed into law, which allows alternatives to animal testing for new drug development. This has opened the door for new pathways to drug discovery and development that involve Artificial Intelligence, cell culture-based assays, and organ-on-chip applications. It also moved the field closer to the three Rs of animal testing:

In 2022, the United States Food and Drug Administration (FDA) approved 37 new drugs, of which 20 were chemical entities and 17 were biologics. In 2023, drug discovery remains strong with many new advancements a result of changing landscapes in both the types of drugs that are being developed and the new and innovative assay that are being launched to evaluate drugs preclinically. Therapeutic development is still highly focused on diseases that affect large populations of people for which there are lack of effective treatments, with 2023’s most anticipated drug launches expected to be in areas of cancer, Alzheimer’s disease, cardiovascular disease, and ulcerative colitis.

The US FDA Modernization Act 2.0 replaces the 1938 Federal Food, Drug and Cosmetic Act which required animal testing prior to human trials. The new law, sponsored in the Senate by Rand Paul and co-sponsored by 11 other bi-partisan senators, eliminates that requirement. Representatives Vern Buchanan and Elaine Luria introduced the companion bill in the House, with over 105 bi-partisan cosponsors. President Biden signed the bill into law in December 2022.

With the advent of modern research methods, we now have many options available to test the efficacy and safety of new pharmaceuticals without requiring the use of animals. Some of these methods include cell-based assays, microphysiological systems like organ-on-a chip (OOC), and bio-printed or computer models. In 2019, the cost of bringing a new drug to market varied greatly from $161 million up to $4.5 Billion[1]. A 2020 study estimated the median cost at a staggering $985.3 million[2]. It can take up to 18 years to bring a new drug to...more

The Butantan Institute, an agency linked to the State Department of Health of São Paulo and one of the largest biomedical research centers in the world, held the 4th edition of the Zebrafish Creation and Management university extension course in December where they exhibited WPI's Zebrafish Microinjection System.

The training is aimed at professionals and post-graduate students involved in zebrafish research as an animal model. The program addressed the physical characteristics, the environment of origin and the way of reproduction and growth of this fish. The coordinators are the researchers Mônica Lopes Ferreira and Carla Lima, responsible for the Zebrafish Platform of CeTICS Butantan whose current capacity holds 6,000 adult fish.

https://www.redezebrafish.com.br/parceiros